uniQure Dirección
Dirección controles de criterios 1/4
uniQure's El consejero delegado es Matt Kapusta , nombrado en Dec 2016, tiene un mandato de 8.92 años. la remuneración anual total es $5.63M , compuesta por 10.8% salario y 89.2% primas, incluidas acciones y opciones de la empresa. posee directamente 0.53% de las acciones de la empresa, por valor de $1.80M . La antigüedad media del equipo directivo y del consejo de administración es de 1.7 años y 6.9 años respectivamente.
Información clave
Matt Kapusta
Chief Executive Officer (CEO)
US$5.6m
Compensación total
| Porcentaje del salario del CEO | 10.8% |
| Permanencia del CEO | 7.3yrs |
| Participación del CEO | 0.7% |
| Permanencia media de la dirección | 1.7yrs |
| Promedio de permanencia en la Junta Directiva | 7.2yrs |
Actualizaciones recientes de la dirección
Recent updates
Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts
Mar 03
uniQure: The Valuation Got More Attractive
Feb 01Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding
Jan 17A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)
Dec 15Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)
Aug 27Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be
Aug 06Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money
Aug 02uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough
Jul 02Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher
Jun 28uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
May 14Is uniQure (NASDAQ:QURE) Using Debt Sensibly?
Apr 11News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat
Mar 01Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?
Dec 09uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion
Sep 21uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch
Aug 30uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
Aug 14uniQure plunges 27% on Q2 revenue miss, postpones higher dose trial of Huntington’s disease therapy
Aug 08These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely
Jun 08uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
May 04uniQure N.V.: Worth A Look Based On Hemophilia B Marketing Applications
Apr 08We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings
Mar 04The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically
Feb 27Is uniQure (NASDAQ:QURE) A Risky Investment?
Feb 23uniQure: Betting On Hemophilia-B Cure
Jan 18UniQure: Leading Gene Therapy Company
Nov 06These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely
Oct 24How We Are Playing UniQure
Oct 04Is uniQure N.V. (NASDAQ:QURE) Trading At A 48% Discount?
Sep 19Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$308m |
| Sep 30 2023 | n/a | n/a | -US$228m |
| Jun 30 2023 | n/a | n/a | -US$187m |
| Mar 31 2023 | n/a | n/a | -US$157m |
| Dec 31 2022 | US$6m | US$609k | -US$127m |
| Sep 30 2022 | n/a | n/a | -US$125m |
| Jun 30 2022 | n/a | n/a | -US$114m |
| Mar 31 2022 | n/a | n/a | US$324m |
| Dec 31 2021 | US$5m | US$583k | US$330m |
| Sep 30 2021 | n/a | n/a | US$321m |
| Jun 30 2021 | n/a | n/a | US$303m |
| Mar 31 2021 | n/a | n/a | -US$139m |
| Dec 31 2020 | US$4m | US$585k | -US$125m |
| Sep 30 2020 | n/a | n/a | -US$166m |
| Jun 30 2020 | n/a | n/a | -US$136m |
| Mar 31 2020 | n/a | n/a | -US$124m |
| Dec 31 2019 | US$4m | US$548k | -US$124m |
| Sep 30 2019 | n/a | n/a | -US$105m |
| Jun 30 2019 | n/a | n/a | -US$103m |
| Mar 31 2019 | n/a | n/a | -US$92m |
| Dec 31 2018 | US$3m | US$502k | -US$83m |
| Sep 30 2018 | n/a | n/a | -US$90m |
| Jun 30 2018 | n/a | n/a | -US$78m |
| Mar 31 2018 | n/a | n/a | -US$78m |
| Dec 31 2017 | US$4m | US$468k | -US$79m |
Compensación vs. Mercado: Matt($USD5.63M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.23M).
Compensación vs. Ingresos: La compensación de Matt ha aumentado mientras la empresa no es rentable.
CEO
Matt Kapusta (51 yo)
7.3yrs
Permanencia
US$5,628,174
Compensación
Mr. Matthew Craig Kapusta, also known as Matt, served as Independent Director at Decibel Therapeutics, Inc. since March 2023 until September 25, 2023. He has been the Chief Executive Officer of uniQure N.V...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Executive Director | 7.3yrs | US$5.63m | 0.67% $ 1.5m | |
| CFO, Principal Financial Officer & GM of Amsterdam Site | 2.8yrs | US$2.13m | 0.16% $ 353.9k | |
| Chief Operating Officer | 2.9yrs | US$2.37m | 0.18% $ 404.1k | |
| Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | no data | sin datos | sin datos | |
| Chief Business & Scientific Officer | less than a year | sin datos | sin datos | |
| Chief Legal & Compliance Officer | less than a year | sin datos | sin datos | |
| Business Development Director | 15.8yrs | sin datos | sin datos | |
| Interim Chief People and Culture Officer | less than a year | sin datos | sin datos | |
| Chief Corporate Affairs Officer | 2.1yrs | US$1.22m | sin datos | |
| Chief Quality Officer | 1.3yrs | sin datos | sin datos | |
| Chief Medical Officer | less than a year | sin datos | sin datos | |
| Vice President of Global Medical Affairs | no data | sin datos | sin datos |
1.7yrs
Permanencia media
53yo
Promedio de edad
Equipo directivo experimentado: QUREEl equipo directivo de la empresa no se considera experimentado ( 1.7 años de permanencia media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Executive Director | 9.3yrs | US$5.63m | 0.67% $ 1.5m | |
| Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | 9.7yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Non-Executive Director | 7.8yrs | US$368.42k | 0.053% $ 121.1k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Non-Executive Director | 6.6yrs | US$357.05k | 0.036% $ 82.4k | |
| Independent Non-Executive Director | 6.6yrs | US$369.55k | 0.036% $ 82.4k | |
| Independent Chairman of the Board | 5.8yrs | US$390.68k | 0.025% $ 58.0k | |
| Independent Non-Executive Director | 10.8yrs | US$355.68k | 0.029% $ 65.4k | |
| Non-Executive Director | 5.5yrs | US$350.68k | 0.079% $ 180.3k |
7.2yrs
Permanencia media
61yo
Promedio de edad
Junta con experiencia: La junta directiva de QURE se considera experimentada (6.9 años de antigüedad promedio).